CompletedPhase 2NCT01093222
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Anthony El-Khoueiry, M.DSWOG Cancer Research Network
- Intervention
- Erlotinib Hydrochloride(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2014
Study locations (30)
- The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Fremont - Rideout Cancer Center, Marysville, California, United States
- Sutter Cancer Research Consortium, Novato, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Valley Medical Oncology Consultants, Pleasanton, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Poudre Valley Hospital, Fort Collins, Colorado, United States
- Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- UF Cancer Center at Orlando Health, Orlando, Florida, United States
- Northeast Georgia Medical Center, Gainesville, Georgia, United States
- Memorial University Medical Center, Savannah, Georgia, United States
- Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States
- Queen's Medical Center, Honolulu, Hawaii, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01093222 on ClinicalTrials.govOther trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07265674A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerJ-Pharma Co., Ltd.
- RECRUITINGPHASE3NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz Pharmaceuticals
- RECRUITINGNCT07007832Bile Omics for Diagnosing Indeterminate Biliary StricturesShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerUniversity of Southern California
See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →